• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在心房颤动中开具低剂量地高辛的益处。

Benefits of prescribing low-dose digoxin in atrial fibrillation.

机构信息

Advanced Research Center for Cardiovascular Pathology and Haemostaseology, Department of Internal Medicine I - Medical Semiology I, 162271"Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.

Family Physician Clinic, Civil Medical Society Dr Rosca, Teremia Mare, Timis, Romania.

出版信息

Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211051955. doi: 10.1177/20587384211051955.

DOI:10.1177/20587384211051955
PMID:34724841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8573519/
Abstract

INTRODUCTION

The role of digoxin (cardiac glycoside) in controlling the heart rate (HR) for the treatment of atrial fibrillation (AF) patients has not been explored in depth.

METHODS

To contribute to the limited data, our team conducted retrospective analysis of the clinical records of 1444 AF patients. We divided the AF patients into two groups, wherein group 1 patients were treated with beta-blockers (BB), low-dose digoxin, and an anticoagulant (vitamin K antagonist/factor-IIa inhibitor/factor-Xa inhibitor), and group 2 patients were treated with just BB and an anticoagulant. Our objectives were to compare the impact of combination therapy of BB and digoxin on the resting HR in patients with permanent AF and the patients' quality of life (QOL) at periodic intervals.

RESULTS

The findings of our study showed a better control of the resting HR rate (<110bpm) and an improved QOL among the group 1 patients when compared with group 2 patients.

CONCLUSION

Our findings are indicative of the favorable clinical outcomes that resulted from the addition of a low-dose of digoxin to the AF treatment regimen. However, larger studies/trials elucidating the outcomes of AF patients treated with the dual rate control therapy are required to clarify the role of digoxin, guide the choice of agents, and standardize the AF treatment protocol.

摘要

简介

地高辛（强心苷）在控制心房颤动（AF）患者心率（HR）方面的作用尚未得到深入探讨。

方法

为了补充有限的数据，我们的团队对 1444 名 AF 患者的临床记录进行了回顾性分析。我们将 AF 患者分为两组，其中一组患者接受β受体阻滞剂（BB）、小剂量地高辛和抗凝剂（维生素 K 拮抗剂/IIa 因子抑制剂/因子 Xa 抑制剂）治疗，另一组患者仅接受 BB 和抗凝剂治疗。我们的目的是比较 BB 和地高辛联合治疗对永久性 AF 患者静息 HR 及患者生活质量（QOL）的影响。

结果

与组 2 相比，组 1 患者静息 HR 率（<110bpm）得到更好的控制，生活质量得到改善。

结论

我们的发现表明，低剂量地高辛加入 AF 治疗方案可带来良好的临床结果。然而，需要更大规模的研究/试验来阐明接受双重速率控制治疗的 AF 患者的结局，以明确地高辛的作用，指导药物选择，并规范 AF 治疗方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98ab/8573519/07ad46f0fb8f/10.1177_20587384211051955-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98ab/8573519/43091f0bd272/10.1177_20587384211051955-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98ab/8573519/eb1dd705037c/10.1177_20587384211051955-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98ab/8573519/07ad46f0fb8f/10.1177_20587384211051955-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98ab/8573519/43091f0bd272/10.1177_20587384211051955-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98ab/8573519/eb1dd705037c/10.1177_20587384211051955-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/98ab/8573519/07ad46f0fb8f/10.1177_20587384211051955-fig3.jpg

相似文献

1
Benefits of prescribing low-dose digoxin in atrial fibrillation.在心房颤动中开具低剂量地高辛的益处。
Int J Immunopathol Pharmacol. 2021 Jan-Dec;35:20587384211051955. doi: 10.1177/20587384211051955.
2
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).地高辛在伴有不良心血管结局的心房颤动患者中的应用：利伐沙班每日一次口服直接 Xa 因子抑制剂与维生素 K 拮抗剂预防心房颤动卒中及栓塞的临床试验（ROCKET AF）的回顾性分析。
Lancet. 2015 Jun 13;385(9985):2363-70. doi: 10.1016/S0140-6736(14)61836-5. Epub 2015 Mar 6.
3
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.心房颤动心率控制综述以及RATE-AF试验的基本原理和方案。
BMJ Open. 2017 Jul 20;7(7):e015099. doi: 10.1136/bmjopen-2016-015099.
4
Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure?卡维地洛单独使用或与地高辛联合使用用于治疗心力衰竭患者的心房颤动？
J Am Coll Cardiol. 2003 Dec 3;42(11):1944-51. doi: 10.1016/j.jacc.2003.07.020.
5
Rate control and clinical outcomes in patients with atrial fibrillation and obstructive lung disease.心房颤动合并阻塞性肺疾病患者的心率控制与临床结局。
Heart Rhythm. 2018 Dec;15(12):1825-1832. doi: 10.1016/j.hrthm.2018.06.044. Epub 2018 Jul 3.
6
Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.地高辛与比索洛尔控制心房颤动患者心率对生活质量影响的比较：RATE-AF 随机临床试验。
JAMA. 2020 Dec 22;324(24):2497-2508. doi: 10.1001/jama.2020.23138.
7
Pharmacologic management of atrial fibrillation: current therapeutic strategies.心房颤动的药物治疗：当前的治疗策略
Am Heart J. 2001 Feb;141(2 Suppl):S15-21. doi: 10.1067/mhj.2001.109952.
8
Digoxin in patients with permanent atrial fibrillation: data from the RACE II study.永久性心房颤动患者使用地高辛：来自RACE II研究的数据。
Heart Rhythm. 2014 Sep;11(9):1543-50. doi: 10.1016/j.hrthm.2014.06.007. Epub 2014 Jun 9.
9
Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study.低剂量地尔硫䓬或倍他洛尔联合地高辛控制慢性心房颤动心室率的疗效与安全性比较研究：随机交叉研究
Int J Cardiol. 1995 Nov 24;52(2):167-74. doi: 10.1016/0167-5273(95)02480-k.
10
The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation.心房颤动节律管理后续调查（AFFIRM）研究：心房颤动的心率控制方法
J Am Coll Cardiol. 2004 Apr 7;43(7):1201-8. doi: 10.1016/j.jacc.2003.11.032.

引用本文的文献

1
Correlation of the FIB-4 Liver Biomarker Score with the Severity of Heart Failure.FIB-4肝脏生物标志物评分与心力衰竭严重程度的相关性。
Medicina (Kaunas). 2024 Nov 26;60(12):1943. doi: 10.3390/medicina60121943.
2
The influence of sepsis on erythrocytes morphology: case report and literature review.脓毒症对红细胞形态的影响：病例报告及文献复习。
Rom J Morphol Embryol. 2024 Jan-Mar;65(1):119-123. doi: 10.47162/RJME.65.1.15.
3
Does COVID-19 Infection during Pregnancy Increase the Appearance of Congenital Gastrointestinal Malformations in Neonates?

本文引用的文献

1
Selecting the right anticoagulant for stroke prevention in atrial fibrillation.选择合适的抗凝药物预防房颤相关性卒中。
Eur Rev Med Pharmacol Sci. 2021 Jul;25(13):4499-4505. doi: 10.26355/eurrev_202107_26241.
2
Post-stroke Quality of Life Index: A quality of life tool for stroke survivors from Sri Lanka.《卒后生活质量指数》：来自斯里兰卡的脑卒中患者生活质量工具。
Health Qual Life Outcomes. 2020 Jul 20;18(1):239. doi: 10.1186/s12955-020-01436-7.
3
Are Inherited Combined Thrombophilia Mutations a Causative or an Additive Factor in Recurrent Venous Thrombotic Accidents?
孕期感染新冠病毒会增加新生儿先天性胃肠道畸形的发生率吗？
Biomedicines. 2023 Nov 21;11(12):3105. doi: 10.3390/biomedicines11123105.
4
Digoxin and Standard-of-Care Therapy for Heart Failure Patients with COVID-19: Analysis of Data from the US Military Health System (MHS) Data Repository.地高辛与COVID-19心力衰竭患者的标准治疗：来自美国军事卫生系统（MHS）数据存储库的数据分析
Drugs Real World Outcomes. 2023 Jun;10(2):299-307. doi: 10.1007/s40801-023-00360-8. Epub 2023 Mar 18.
5
Evaluation of Non-Pharmacological Measures Implemented in the Management of the COVID-19 Pandemic in Romania.罗马尼亚新冠疫情管理中实施的非药物措施评估
Healthcare (Basel). 2022 Sep 13;10(9):1756. doi: 10.3390/healthcare10091756.
6
A Review of the Role of Transthoracic and Transesophageal Echocardiography, Computed Tomography, and Magnetic Resonance Imaging in Cardioembolic Stroke.经胸超声心动图和经食管超声心动图、计算机断层扫描和磁共振成像在心源性卒中中的作用评价。
Med Sci Monit. 2022 Jun 22;28:e936365. doi: 10.12659/MSM.936365.
7
Cardiovascular Risk Prediction Parameters for Better Management in Rheumatic Diseases.用于改善风湿性疾病管理的心血管风险预测参数。
Healthcare (Basel). 2022 Feb 7;10(2):312. doi: 10.3390/healthcare10020312.
8
Identification of Heavy Tobacco Smoking Predictors-Influence of Marijuana Consuming Peers and Truancy among College Students.重度吸烟预测因素的识别——大学生中吸食大麻的同伴及逃学的影响
Healthcare (Basel). 2021 Dec 1;9(12):1666. doi: 10.3390/healthcare9121666.
Clin Lab. 2019 Jul 1;65(7). doi: 10.7754/Clin.Lab.2019.181221.
4
Evaluation of the DOAC-Stop® Procedure to Overcome the Effect of DOACs on Several Thrombophilia Screening Tests.评估DOAC-Stop®程序以克服直接口服抗凝剂（DOACs）对多项血栓形成倾向筛查试验的影响。
TH Open. 2018 Jun 1;2(2):e202-e209. doi: 10.1055/s-0038-1657785. eCollection 2018 Apr.
5
Gender Differences in Atrial Fibrillation: A Review of Epidemiology, Management, and Outcomes.心房颤动中的性别差异：流行病学、管理及结局综述
Curr Cardiol Rev. 2019;15(2):136-144. doi: 10.2174/1573403X15666181205110624.
6
Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?β受体阻滞剂还是地高辛用于心房颤动和心力衰竭？
Card Fail Rev. 2016 May;2(1):35-39. doi: 10.15420/cfr.2015:28:2.
7
A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trial.心房颤动心率控制综述以及RATE-AF试验的基本原理和方案。
BMJ Open. 2017 Jul 20;7(7):e015099. doi: 10.1136/bmjopen-2016-015099.
8
The search for atrial fibrillation and its impact on public health.对心房颤动及其对公众健康影响的研究。
Swiss Med Wkly. 2017 Jun 30;147:w14447. doi: 10.4414/smw.2017.14447. eCollection 2017.
9
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.2016年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动管理指南。
Eur J Cardiothorac Surg. 2016 Nov;50(5):e1-e88. doi: 10.1093/ejcts/ezw313. Epub 2016 Sep 23.
10
Diagnosis and Treatment of Atrial Fibrillation.心房颤动的诊断与治疗
Am Fam Physician. 2016 Sep 15;94(6):442-52.